Single Dose Mpcs
Lumbar Disk Degenerative Disorder
Explore 8 assets in Lumbar Disk Degenerative Disorder →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Mesoblast, Ltd.
Modality
Cell therapy
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01290367CT.gov Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lumbar Disk Degenerative Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Single Dose Mpcs (this asset) | Mesoblast, Ltd. | P2 | B · 57 |
| Nepenthe | Brigham and Women's Hospital | P4 | BB |
| Oxycodone | Brigham and Women's Hospital | P4 | BB |
| Ibuprofen | St Joseph University, Beirut, Lebanon | P4 | BB |
| Pentoxifylline | St Joseph University, Beirut, Lebanon | P4 | BB |
| Rexlemestrocel-L | Mesoblast, Ltd. | P3 | BB |
| Autologous Conditioned Plasma | Allmed Medical Center | P2 | BB |
| Allogeneic Bone Marrow-Derived Mscs | University Hospital, Montpellier | P2/3 | CCC |
| Matrilin-3 | Inbo Han | P1/2 | CCC |
+6 more in the Lumbar Disk Degenerative Disorder cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Single Dose Mpcs in Lumbar Disk Degenerative Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/single-dose-mpcs-lumbar-disk-degenerative-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →